The iCON brand aims to offer flexible, rapidly deployable systems for biopharmaceutical manufacturing.
Integrated Project Services, LLC (IPS) and G-CON Manufacturing, Inc. have launched iCON, to leverage both partners’ experience in engineering and construction, and in modular technology. The collaboration would focus on engineering using G-CON’s pre-fabricated process modules (PODs) to reduce construction costs and time to market for biopharmaceutical manufacturers.
“In our industry, we are seeing a paradigm shift away from capital intensive facilities to rapidly deployable and process intensified infrastructures,” said Maik Jornitz, CEO of G-CON. Among the additional services offered will be 3-D walkthroughs and process modeling.
“There is an overwhelming desire and need for flexibility in the biotechnology industry; we hear it every day,” said Tom Piombino, biotechnology process architect and senior director at IPS. “It is clear that the design philosophies, the science and the classic biomanufacturing processes are flexing in preparation for new and modified therapeutic platforms. iCON delivers rapid capacity scaling in a multi-platform, multi-product environment and seeks to reduce the long term delay and capital investment associated with change,” he said.
Partners describe the hallmarks of iCON’s platform as collaboration on cost effective pre-engineered building delivery and work with key bioprocess and single-use process equipment vendors, resulting in turnkey facilities that can be deployed on a fast-track basis to most regions of the world.
Source: Company press release
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.